Filtered By:
Condition: Cholesterol

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 572 results found since Jan 2013.

Exosomes loaded with PTEN siRNA leads to functional recovery after complete transection of the spinal cord by specifically targeting the damaged area
ConclusionMSC-exo were extracted from Human bone marrow mesenchymal stem cells. All rats had complete transection of the spinal cord. MSC-exo were loaded with co-incubation together with siRNA for PTEN conjugated to cholesterol. The MSC-exo were given by intranasal administration 1-4 hours post-SCI.
Source: Cytotherapy - May 24, 2019 Category: Cytology Source Type: research

FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C)
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) Leqvio provides effective and sustained LDL-C reduction of up to 52% vs. placebo...
Source: Drugs.com - New Drug Approvals - December 22, 2021 Category: Drugs & Pharmacology Source Type: news

Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma
In this study, we utilize the engineering technology to generate T7 peptide-decorated exosome (T7-exo). T7 is a peptide specifically binding to the transferrin receptor. T7-exo shows excellent packaging and protection of cholesterol-modified Cy3-siYY1 while quickly releasing payloads in a cytoplasmic reductive environment. The engineered exosomes T7-siYY1-exo could deliver more effciently to GBM cells both in vitro and in vivo. Notably, in vitro experiments demonstrate that T7-siYY1-exo can enhance chemoradiotherapy sensitivity and reverse therapeutic resistance. Moreover, T7-siYY1-exo and TMZ/IR exert synergistic anti-GBM...
Source: Frontiers in Pharmacology - August 19, 2022 Category: Drugs & Pharmacology Source Type: research

Translational Population-Pharmacodynamic Modeling of a Novel Long-Acting siRNA Therapy, Inclisiran, for the Treatment of Hypercholesterolemia
Clin Pharmacol Ther. 2022 Oct 25. doi: 10.1002/cpt.2774. Online ahead of print.ABSTRACTInclisiran is a novel N-acetylgalactosamine (GalNAc) conjugated small-interfering ribonucleic acid (siRNA) therapy designed to specifically target proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA in the liver for the treatment of hypercholesterolemia. Inclisiran's GalNAc attachment results in a rapid uptake into the liver, and thus a short plasma half-life, but long duration of effects on PCSK9 inhibition and low-density lipoprotein cholesterol (LDL-C) lowering. The effects on PCSK9 inhibition and consequent LDL-C reduction are...
Source: Clinical Pharmacology and Therapeutics - October 25, 2022 Category: Drugs & Pharmacology Authors: Nathalie H Gosselin Virna J A Schuck Olivier Barriere Kenneth Kulmatycki Alison Margolskee Patrick Smith YanLing He Source Type: research

siRNA screening reveals that SNAP29 contributes to exosome release
Cell Mol Life Sci. 2023 Jun 7;80(7):177. doi: 10.1007/s00018-023-04822-8.ABSTRACTCells release extracellular vesicles (EVs) of different sizes. Small EVs (< 200 nm) can originate from the fusion of multivesicular bodies with the plasma membrane, i.e. exosomes, and from budding of the plasma membrane, i.e. small ectosomes. To investigate the molecular machinery required for the release of small EVs, we developed a sensitive assay based on incorporation of radioactive cholesterol in EV membranes and used it in a siRNA screening. The screening showed that depletion of several SNARE proteins affected the release of small EV...
Source: Cellular and Molecular Life Sciences : CMLS - June 7, 2023 Category: Cytology Authors: Nina Pettersen Hessvik Krizia Sagini Silvana Romero Manuel Ramirez-Garrastacho Marta Rodriguez Astrid Elisabeth V Tutturen Audun Kvalvaag Espen Stang Andreas Brech Kirsten Sandvig Alicia Llorente Source Type: research

Estimating the potential impact of LDL-C lowering through SIRNA therapies on population health: A simulation study
Background and Aims: Inclisiran, an siRNA therapy, provides sustained reductions in LDL-C. Potential CV benefits of inclisiran, as an adjunct to statins, were evaluated through simulation.
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: K. Ray, L. Gunn, L.G. Conde, F. Raal, R.S. Wright, N. Gosselin, L. Leiter, W. Koenig, G. Schwartz, U. Landmesser Source Type: research

Suppression of FGF5 and FGF18 Expression by Cholesterol-Modified siRNAs Promotes Hair Growth in Mice
FGF5 and FGF18 are key factors in the regulation of the hair follicle cycle. FGF5 is overexpressed during the late anagen phase and serves as a crucial regulatory factor that promotes the anagen-to-catagen transition in the hair follicle cycle. FGF18, which is overexpressed during the telogen phase, mainly regulates the hair follicle cycle by maintaining the telogen phase and inhibiting the entry of hair follicles into the anagen phase. The inhibition of FGF5 may prolong the anagen phase, whereas the inhibition of FGF18 may promote the transition of the hair follicles from the telogen phase to the anagen phase. In the pres...
Source: Frontiers in Pharmacology - July 7, 2021 Category: Drugs & Pharmacology Source Type: research

Genetic Regulation of Liver Metabolites and Transcripts Linking to Biochemical-Clinical Parameters
Conclusion In summary, this study is the first to combine metabolomics, transcriptomics, and genome-wide association studies in a porcine model. Our results improve understanding of the genetic regulation of metabolites which link to transcripts and finally biochemical-clinical parameters. Further, high-performance profiling of metabolites as intermediate phenotypes is a potentially powerful approach to uncover how genetic variation affects metabolic and health status. Our results advance knowledge in areas of biomedical and agricultural interest and identify potential correlates of biomarkers, SNPs-metabolites, SNPs-tran...
Source: Frontiers in Genetics - April 16, 2019 Category: Genetics & Stem Cells Source Type: research

Tangshen Formula Alleviates Hepatic Steatosis by Inducing Autophagy Through the AMPK/SIRT1 Pathway
Conclusion In conclusion, the present study demonstrated that autophagy was involved in relieving the effects of TSF against NAFLD, which were mediated by the AMPK/SIRT1 pathway (Figure 7D). These findings may improve our current understanding of the role of TSF in treating hepatic steatosis and provide an experimental basis for the clinical application of TSF in NAFLD and its related metabolic syndrome. Ethics Statement This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Ethics Co...
Source: Frontiers in Physiology - April 25, 2019 Category: Physiology Source Type: research